Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug814 | CVnCoV 8 μg (4 μg double dose) Wiki | 1.00 |
| drug812 | CVnCoV 6 μg Wiki | 1.00 |
| drug3020 | Pneumococcal vaccine Wiki | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
| D018352 | Coronavirus Infections NIH | 0.04 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has caused a global pandemic and is associated with significant morbidity and mortality. The mortality rate for COVID-19 patients admitted to an intensive care unit (ICU) who require mechanical intubation is approximately 75%. While the pathophysiology of severe COVID-19 has yet to be fully understood, it is possible that a combination of high viral loads and an overactive dysregulated inflammatory response may contribute. Therefore, the clearance of SARS-CoV-2 virus and cytokines could provide a more opportunistic environment for the innate immune system to clear the virus and establish lasting immunity. The Seraph®-100 Microbind® Affinity Blood Filter (Seraph®-100) is an extracorporeal broad-spectrum sorbent hemoperfusion filter for removing virus and cytokines from the blood. The FDA authorized an Emergency Use Authorization (EUA) for treatment of severe COVID-19 with the Seraph®-100. As part of the EUA, this registry study will collect de-identified data to assess safety and efficacy on the use of Seraph®-100 Microbind® Affinity Blood Filter in the treatment of COVID-19 patients.
Description: Monitor and report on adverse events and unanticipated adverse device effects experienced by patients receiving treatment with the Seraph®-100 for COVID-19, including but not limited to: bleeding, clotting, cardiac dysrhythmia, hypotension, increase in oxygen requirement, hemolytic anemia, and allergic/anaphylactic reaction
Measure: Rate of known, expected, or unanticipated adverse device effects Time: From the initiation of therapy through 24 hours after therapy has been completedDescription: Measure change in Mean Arterial Pressure before and after treatment with the Seraph®-100 device
Measure: Change in cardiovascular hemodynamic stability Time: 24 hours prior to therapy through 24 hours after therapy has been completedDescription: Measure change in required Vasopressor Dosages before and after treatment with the Seraph®-100 device
Measure: Change in cardiovascular hemodynamic support Time: 24 hours prior to therapy through 24 hours after therapy has been completedDescription: Measure change in required Respiratory Support before and after treatment with the Seraph®-100 device
Measure: Change in pulmonary/respiratory status Time: 24 hours prior to therapy through 24 hours after therapy has been completedDescription: Measure change in Interleukin-6 (IL-6) before and after treatment with the Seraph®-100 device
Measure: Change in laboratory measures of cytokine reactions and/or viral sepsis: IL-6 Time: 24 hours prior to therapy through 24 hours after therapy has been completedDescription: Measure change in C-Reactive Protein (CRP) before and after treatment with the Seraph®-100 device
Measure: Change in laboratory measures of cytokine reactions and/or viral sepsis: CRP Time: 24 hours prior to therapy through 24 hours after therapy has been completedDescription: Measure change in Ferritin before and after treatment with the Seraph®-100 device
Measure: Change in laboratory measures of cytokine reactions and/or viral sepsis: Ferritin Time: 24 hours prior to therapy through 24 hours after therapy has been completedDescription: Measure change in D-Dimer before and after treatment with the Seraph®-100 device
Measure: Change in laboratory measures of cytokine reactions and/or viral sepsis: D-Dimer Time: 24 hours prior to therapy through 24 hours after therapy has been completedDescription: Measure change in Absolute Lymphocyte Count (ALC) before and after treatment with the Seraph®-100 device
Measure: Change in laboratory measures of cytokine reactions and/or viral sepsis: ALC Time: 24 hours prior to therapy through 24 hours after therapy has been completedAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports